Loading organizations...
DNV Capital is an international investment institution funding companies generating new productive forces in healthcare and hard technology. The firm provides strategic equity investments, mergers and acquisitions, and project financing, leveraging global expertise. It targets growth to mature stage companies across pharmaceuticals, medical devices, AI healthcare, advanced materials, and aerospace.
Founded by seasoned investment professionals, DNV Capital's team includes Managing Partner Kevin Lin and Partner Frank Wang. Mr. Lin offers over two decades in financial and strategic investment from CDF Capital and CDH Investments. Mr. Wang brings over 20 years of venture capital and TMT operations expertise from Morgan Creek Capital and KPCB China. Their insight targeted high-growth, innovative sectors.
DNV Capital supports entrepreneurs and investors via its international asset management platform, backing exceptional companies. Mission fosters innovation and breakthroughs in healthcare and hard tech. The firm contributes to developing transformative industries, cultivating new value globally.
DNV Capital has 1 tracked investment across 1 company. The latest tracked deal is $147.6M Series C in Hinova Pharma in October 2020.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Oct 7, 2020 | Hinova Pharma | $147.6M Series C | — | Huarong Rongde, Infinity Group, Tigermed |
